|
1. A method for treating a human having lymphoma, said method comprising administering to said human a composition comprising pre-formed nanoparticle/antibody complexes comprising albumin-paclitaxel nanoparticles and an anti-CD20 monoclonal antibody, wherein albumin is complexed to the anti-CD20 monoclonal antibody in the pre-formed nanoparticle/antibody complexes, wherein the nanoparticle/antibody complexes have been pre-formed in vitro by mixing aqueous albumin-paclitaxel nanoparticles with the anti-CD20 monoclonal antibody under conditions to form the nanoparticle/antibody complexes, wherein the conditions comprise incubating at least 5 mg/ml aqueous albumin-paclitaxel nanoparticles with the anti-CD20 monoclonal antibody at a weight ratio of 5:1, 5:2, 5:3, 5:4 or 1:1 albumin-paclitaxel nanoparticle to antibody and for between about 5 minutes and about 400 minutes and diluting the pre-formed nanoparticle/antibody complexes prior to administration, such that the nanoparticle/antibody complexes have CD20 binding specificity and an average diameter of said complexes is between 0.15 μm and 0.9 μm; said nanoparticle/antibody complexes suitable for administration under conditions wherein a length of progression-free survival is increased, wherein a B-cell or T-cell expresses CD20.
|